Elutia (ELUT) AI Stock Analysis

• Market Cap: $39.00M
• Dividend Yield: N/A
• Average Volume (3M): 364.18K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.06
• Revenue Growth: -14.92%
• EPS Growth: 72.81%
• Country: US
• Employees: 51
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.19
• Shares Outstanding: 38,081,936
• 10 Day Avg. Volume: 362,745
• 30 Day Avg. Volume: 364,181
• PEG Ratio: 0.20
• Price to Book (P/B): -2.35
• Price to Sales (P/S): 4.46
• P/FCF Ratio: -4.66
• Enterprise Value/Market Cap: 3.09
• Enterprise Value/Revenue: 5.72
• Enterprise Value/Gross Profit: 12.44
• Enterprise Value/Ebitda: -7.97
• 1Y Price Target: $3.50
• Price Target Upside: 407.25% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $0.68 ▼(-2.17% Downside)

The overall stock score is primarily impacted by significant financial challenges, including high operating losses and negative equity. While the earnings call provided some positive strategic developments, the technical analysis and valuation metrics indicate ongoing bearish trends and limited immediate return potential.

Positive Factors

Strategic Divestiture

The sale of the bioenvelope business enhances Elutia's financial position and validates its technology platform, providing resources for future growth and strategic focus on core product lines.

Improved Gross Margins

Improved gross margins indicate better cost management and operational efficiency, which can lead to enhanced profitability and competitive positioning in the long term.

Cardiovascular Segment Growth

Strong growth in the cardiovascular segment reflects successful market penetration and product acceptance, supporting sustained revenue expansion and market presence.

Negative Factors

Financial Instability

Negative equity and high leverage pose risks to financial sustainability, potentially limiting the company's ability to invest in growth and manage economic downturns.

Declining Revenue

Declining revenue signals challenges in maintaining market share and growth, which could impact long-term financial health and strategic initiatives.

Legacy Litigation Liability

Ongoing litigation liabilities could result in financial penalties and distract management from strategic priorities, affecting long-term operational focus and financial resources.

Elutia Business Overview & Revenue Model

Company Description

Aziyo Biologics (ELUT) is a biotechnology company focused on developing regenerative medicine solutions, primarily through the utilization of human-derived extracellular matrix (ECM) technology. The company operates in the medical device and tissue regeneration sectors, offering innovative products for surgical and wound care applications. Aziyo's core products include grafts and implants that promote healing and tissue regeneration, addressing critical medical needs in areas such as orthopedics, cardiovascular, and general surgery.

How the Company Makes Money

Aziyo Biologics generates revenue through the sale of its biologic products, which include tissue grafts and implants derived from human ECM. The company primarily targets hospitals and surgical centers, where its products are utilized in various surgical procedures. Key revenue streams include direct sales of its product lines, as well as potential licensing agreements with larger medical device companies that seek to incorporate Aziyo's innovative technology into their offerings. Significant partnerships with healthcare providers and participation in clinical studies also enhance its market presence and drive sales growth.

Elutia Financial Statement Overview

Summary

Aziyo Biologics is facing significant financial challenges, with declining revenues, high operating losses, and negative equity. Despite a stable gross profit margin, the overall financial health is weak, requiring strategic interventions to improve profitability and reduce leverage.

Income Statement

Aziyo Biologics has faced declining revenue growth, with a negative growth rate of -10.97% in the TTM. The company is experiencing significant losses, as indicated by negative net profit, EBIT, and EBITDA margins. The gross profit margin is relatively stable at 48.35%, but overall profitability is severely impacted by high operating losses.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, leading to a negative debt-to-equity ratio. This indicates financial instability and high leverage. The return on equity is positive due to negative equity, but this is misleading as it reflects significant losses rather than profitability. The equity ratio is also negative, highlighting potential solvency issues.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a slight improvement in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that cash flow is somewhat aligned with reported losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.08M	24.38M	24.75M	23.85M	47.39M	42.68M
Gross Profit	9.69M	10.71M	11.05M	11.64M	19.02M	20.56M
EBITDA	-15.13M	-45.89M	-31.92M	-27.30M	-15.72M	-12.30M
Net Income	-26.47M	-53.95M	-37.66M	-32.90M	-24.83M	-21.82M
Balance Sheet
Total Assets	29.41M	36.13M	43.43M	68.84M	67.17M	82.81M
Cash, Cash Equivalents and Short-Term Investments	4.72M	13.24M	19.28M	16.99M	30.39M	39.15M
Total Debt	26.32M	24.74M	23.95M	25.45M	23.24M	30.64M
Total Liabilities	73.33M	82.39M	82.03M	73.87M	53.65M	61.98M
Stockholders Equity	-43.92M	-46.26M	-38.60M	-5.03M	13.52M	20.83M
Cash Flow
Free Cash Flow	-29.85M	-23.31M	-22.11M	-21.97M	-15.81M	-14.27M
Operating Cash Flow	-29.37M	-22.66M	-21.76M	-21.43M	-15.45M	-13.63M
Investing Cash Flow	-486.00K	-474.00K	14.21M	-540.00K	-369.00K	-640.00K
Financing Cash Flow	12.61M	17.09M	9.84M	8.54M	6.71M	51.21M

Elutia Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.69
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELUT, the sentiment is Negative. The current price of 0.69 is below the 20-day moving average (MA) of 0.70, below the 50-day MA of 0.82, and below the 200-day MA of 1.82, indicating a bearish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 42.33 is Neutral, neither overbought nor oversold. The STOCH value of 40.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELUT.

Elutia Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ELUT	45 Neutral	$39.00M	-0.87	―	―	-14.92%	72.81%
OKUR	42 Neutral	$41.94M	-0.58	-115.64%	―	―	46.20%
IGC	41 Neutral	$35.78M	-4.85	-83.34%	―	-6.51%	58.31%
PYPD	41 Neutral	$62.63M	―	-390.53%	―	―	61.23%
SONN	40 Underperform	$22.65M	-0.39	―	―	1689.52%	66.05%
RANI	32 Underperform	$167.70M	―	―	―	―	25.08%

Elutia Corporate Events

Aziyo Biologics Faces Nasdaq Delisting Risk Notice

On November 7, 2025, Elutia Inc., a Delaware corporation, received a notification from Nasdaq regarding its Class A common stock, which had a closing bid price below $1.00 for 30 consecutive business days, risking non-compliance with Nasdaq’s listing requirements. The company has been given a 180-day compliance period to rectify this issue, with potential for an additional 180-day period if necessary. Elutia intends to monitor the situation closely and explore options to maintain its Nasdaq listing, though there is no assurance of compliance.

The most recent analyst rating on (ELUT) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.

Elutia’s Earnings Call: Strategic Moves Amid Challenges

Elutia’s recent earnings call conveyed a mixed sentiment, reflecting both significant achievements and ongoing challenges. The company has made strategic strides, notably with the sale of its bioenvelope business, which has positively impacted its financial standing. However, it continues to face hurdles such as declining overall sales and historical revenue issues with SimpliDerm, alongside ongoing litigation liabilities.

Elutia Inc. Advances NXT-41x Amid Financial Developments

Elutia Inc., a company specializing in drug-eluting biomatrix technologies, operates within the medical device industry, focusing on enhancing the compatibility between medical devices and patients. The company aims to humanize medicine by developing products that allow patients to thrive without compromise.

Aziyo Biologics Welcomes Guido J. Neels to Board

On October 10, 2025, Elutia Inc. announced the election of Guido J. Neels to its Board of Directors, effective October 9, 2025, and his appointment to the Audit Committee. This move follows the resignations of board members Maybelle Jordan and W. Matthew Zuga, effective October 8, 2025. Neels, with over 40 years of experience in the medical technology sector, is expected to provide valuable insights as Elutia focuses on leveraging its drug-eluting biomatrix technology to build shareholder value, particularly after its recent EluPro divestiture.

The most recent analyst rating on (ELUT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.

Elutia Completes Sale of BioEnvelope to Boston Scientific

On October 1, 2025, Elutia Inc. announced the completion of the sale of its BioEnvelope business to Boston Scientific Corporation for $88 million. This strategic divestiture allows Elutia to concentrate on advancing its NXT-41x biomatrix platform, which targets reconstruction infections post-mastectomy. The sale strengthens Elutia’s financial position, enabling the company to fully fund the development and launch of NXT-41x, a product poised to capture a significant share of the $1.5 billion U.S. market for breast reconstruction biologics. The transaction also included a non-competition agreement and transitional support services to ensure a smooth transfer of the CIED Business assets.

The most recent analyst rating on (ELUT) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.

Elutia Sells Device Business to Boston Scientific

On September 8, 2025, Elutia Inc. entered into an agreement to sell its cardiac implantable electronic device business to Boston Scientific Corporation for $88 million. This transaction is expected to close in the fourth quarter of 2025 and will allow Elutia to focus on its drug-eluting biomatrix solutions in breast reconstruction, strengthen its financial position, and eliminate outstanding debt. The sale marks a strategic shift for Elutia, enabling it to advance its SimpliDerm franchise and drug-eluting pipeline without shareholder dilution, thereby enhancing long-term shareholder value.

The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.

Aziyo Biologics Reports Strong EluPro Growth

The recent earnings call for Aziyo Biologics, Inc. Class A was marked by a positive sentiment, underscored by significant growth and successful product launches, particularly with EluPro. The company reported improved gross margins and progress in litigation settlements, although challenges persist with SimpliDerm’s performance and ongoing litigation issues.

Elutia Inc. Amends Credit Agreement with SWK Funding

On August 15, 2025, Elutia Inc. amended its Credit Agreement initially established on August 10, 2022, with SWK Funding LLC and other lenders. The amendment involves capitalizing accrued interest and amendment fees into the principal balance of a $25 million senior secured term loan, potentially impacting the company’s financial obligations and liquidity management.

The most recent analyst rating on (ELUT) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aziyo Biologics stock, see the ELUT Stock Forecast page.

Elutia Inc. Reports Strong Growth and Strategic Advances

Elutia Inc., a pioneer in drug-eluting biomatrix technologies, focuses on developing and commercializing products that enhance compatibility between medical devices and patients, primarily in the healthcare sector. The company is known for its innovative solutions aimed at improving patient outcomes.